Bone Biologics faces Nasdaq delisting risk after shares stay below $1 bid price threshold
BBLG•Reverse stock split plan
Management plans to seek shareholder approval for a reverse stock split at its annual meeting to lift the share price.
Nasdaq bid-price notice and compliance deadline
Nasdaq flagged Bone Biologics for failing to meet the $1 minimum bid-price rule, based on 30 consecutive business days of closing bids.
The company has until March 9, 2027 to regain compliance by posting a closing bid of at least $1 for 10 straight sessions.
Failure to cure could trigger a delisting notice, with the option to appeal to a Nasdaq hearings panel.
